Name: ASTRAZENECA PLC-SPONS ADR (AZN) Stock
Brand: ASTRAZENECA PLC-SPONS ADR
Rating: 8 (3 reviews)

AZN Latest News, Press Relases and Analysis

All

Press Releases

20 days ago - By: Chartmill

AstraZeneca PLC-SPONS ADR (NASDAQ:AZN) Passes Key Quality Investing Screen for Long-Term Growth

2 hours ago - By: AstraZeneca

ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab approved in the US as first new treatment in a decade for the 1st-line treatment of patients with HER2-positive metastatic breast cancer

5 days ago - By: The Motley Fool - Mentions: IONQ

What to Watch With IonQ Stock in 2026

11 days ago - By: AstraZeneca

AstraZeneca advances hematology and cell therapy ambition with largest-ever presence at ASH

12 days ago - By: Zacks Investment Research - Mentions: CRMD ADMA ARQT

AZN's Baxdrostat Gets FDA Priority Tag for Uncontrolled Hypertension

12 days ago - By: Zacks Investment Research

Why Astrazeneca (AZN) is a Top Momentum Stock for the Long-Term

13 days ago - By: Zacks Investment Research - Mentions: PFE BMY MRK

Pfizer's Cancer Drugs Deliver Growth Amid Competitive Pressure

13 days ago - By: AstraZeneca

Baxdrostat New Drug Application accepted under FDA Priority Review in the US for patients with hard-to-control hypertension

14 days ago - By: Zacks Investment Research - Mentions: PFE LLY AMGN

AMGN Up Almost 16% in a Month: Should You Buy, Sell or Hold the Stock?

14 days ago - By: Stocktwits - Mentions: PPH IHE PJP TSLA

US-UK Near Landmark Zero-Tariffs Pharma Deal, Announcement Expected Soon: Report

17 days ago - By: Zacks Investment Research - Mentions: JNJ PFE MRK

JNJ's Oncology Momentum Builds as It Chases $50B Goal by 2030

17 days ago - By: Zacks Investment Research

Here's Why Astrazeneca (AZN) is a Strong Growth Stock

18 days ago - By: Zacks Investment Research - Mentions: MRK CDTX SMMT

AstraZeneca or Merck: Which Oncology Giant Has the Edge?

18 days ago - By: Zacks Investment Research

Why Astrazeneca (AZN) is a Top Value Stock for the Long-Term

19 days ago - By: Stocktwits - Mentions: LABU NVO TEVA ABBV ...

Biotech Bull ETF Surges To 20-Month High: Analysts Say Medicare’s Drug-Pricing Blow Is Softer Than Feared

19 days ago - By: Investor's Business Daily - Mentions: RY RY.CA NVO TEVA ...

Medicare Slashes Ozempic's Price Tag 71%; Why Novo Nordisk Rallied

19 days ago - By: Zacks Investment Research - Mentions: SNY MRK

Will Soft Gardasil Demand Continue to Dampen Merck's Top Line?

19 days ago - By: AstraZeneca

IMFINZI® approved in the US as first and only perioperative immunotherapy for patients with early gastric and gastroesophageal cancers

24 days ago - By: The Motley Fool

Why AstraZeneca Stock Bumped Higher Today

24 days ago - By: AstraZeneca

AstraZeneca plans $2 billion manufacturing investment in Maryland, supporting 2,600 jobs and catalyzing economic growth

24 days ago - By: Zacks Investment Research - Mentions: IRWD ABBV

Can Linzess Continue to Aid IRWD's Top Line After a Strong Q3?

24 days ago - By: Zacks Investment Research - Mentions: MRK ADMA EDIT

AZN Wins FDA Nod for Expanded Use of Rare Disease Drug, Koselugo

24 days ago - By: Zacks Investment Research - Mentions: PFE BMY MRK

PFE's New & Acquired Drugs Drive Non-COVID Comeback as LOE Test Looms

25 days ago - By: Benzinga

FDA Approval Delivers Momentum For AstraZeneca's Rare Disease Portfolio

a month ago - By: Zacks Investment Research - Mentions: JNJ LLY ABBV

AbbVie Stock Rebounds After Q3 Dip: Time to Buy, Hold or Sell?

a month ago - By: Investor's Business Daily - Mentions: JNJ PFE

Johnson & Johnson Inks A $3.05 Billion Deal In Cancer Treatment

a month ago - By: Benzinga - Mentions: VRTX HUM UNH REPL ...

10 Health Care Stocks With Whale Alerts In Today's Session

a month ago - By: Zacks Investment Research - Mentions: IRWD ABBV

IRWD Rises 110% in a Month: Should You Buy, Sell or Hold the Stock?

a month ago - By: Zacks Investment Research

Why Astrazeneca (AZN) is a Top Growth Stock for the Long-Term

a month ago - By: Zacks Investment Research - Mentions: IRWD ABBV RLAY

IRWD Beats on Q3 Earnings & Revenues, Raises 2025 View, Stock Soars

a month ago - By: AstraZeneca

Baxdrostat demonstrated a statistically significant and highly clinically meaningful placebo-adjusted reduction of 14.0 mmHg in 24-hour ambulatory systolic blood pressure in patients with resistant hypertension in the Bax24 Phase III trial

a month ago - By: Zacks Investment Research - Mentions: PFE NVO MTSR

Pfizer Discusses Drug Pricing Deal, Metsera Buyout Dispute on Q3 Call